Conditions: LQT2 Syndrome
Keywords: Congenital Long QT Syndrome LQTS Sudden Cardiac Death
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.

Detailed description:

Arms:
arm 1: Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3. arm 2: Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3. arm 3: Participants will receive placebo to match eleclazine on Days 1 to 4.

Interventions: intervention 1: Eleclazine intervention 2: Placebo
Intervention descriptions: intervention 1: Tablets administered orally in a single dose intervention 2: Placebo to match tablets administered orally in a single dose

Protocol document: